Do entheogen-induced mystical experiences boost the immune system? Psychedelics, peak experiences, and wellness

The paper outlines a theoretical link between entheogen-induced mystical experiences and immune function. Earlier work shows that emotionally positive daily events correlate with measures of immune activity (notably salivary immunoglobulin A, sIgA), that some spontaneous remissions of illness have been reported in clinical literature, and that mystical or peak experiences share a characteristic cluster of cognitions, emotions, perceptions and behaviours. Entheogens (psychedelic substances used in religious or sacral contexts) can produce such mystical experiences — described variously as unitive consciousness, peak experiences or intense religious encounters — and the author asks whether these drug‑induced states might similarly influence the immune system and thereby be associated with wellness outcomes. B. advances what the paper terms the "Emxis hypothesis": that mystical experiences occasioned by entheogens can boost immune function. The author highlights sIgA as a practical, non‑invasive proxy indicator of mucosal and, by extension, broader immune responsiveness, and suggests that the hypothesis centres on whether features of mystical experience (for example, intense positive affect, feelings of cosmic belonging and reduced stress) map onto improved sIgA and related immune markers. The introduction furthermore distinguishes contexts and dosing regimens — noting that low‑dose psychedelic adjuncts used to facilitate psychotherapy do not reliably produce mystical states and therefore fall outside the hypothesis, whereas single high‑dose psychedelic therapy sessions intended to produce a unitive or mystical state are the relevant intervention for testing the idea.

The author reviews indirect and suggestive evidence while emphasising the paucity of direct, causal data. Studies of social support, positive psychological mood and desirable daily events show correlations with increased sIgA, and the author argues these parallels provide some conceptual support for the Emxis hypothesis. The discussion presents a cluster view: mystical experiences, positive daily events linked to raised sIgA, and certain accounts of spontaneous remission share overlapping phenomenology, which invites the question whether powerful positive or mystical states could strengthen immunity to an extent associated with unusual clinical outcomes. At the same time, the author acknowledges substantial uncertainty. Much of the cited evidence is correlational, so causality is ambiguous: mystical experiences might promote better immune markers, immune changes might predispose to certain psychological states, or a third factor (for example, personality traits) could account for observed associations. The author notes that some reviews and compilations (cited in the extracted text) find few convincing demonstrations of a link between mystical states and spontaneous remissions, tempering expectations about large or consistent clinical effects. To resolve these ambiguities the author recommends experimental, controlled research using entheogens. Suggested elements include using high‑dose psychedelic therapy designed to elicit mystical experiences, measuring sIgA (and possibly other immune indicators) before and after sessions, and distinguishing sessions that produce primarily positive unitive experiences from those that are emotionally adverse as a kind of internal control. The discussion also emphasises the need to differentiate kinds of mystical experience (everyday uses of marijuana, low‑dose LSD adjuncts in psychotherapy, and intensive high‑dose entheogenic ceremonies are not equivalent) because the immune consequences may depend on the qualitative nature of the experience. Finally, the author stresses practical and ethical considerations: that any experimental work should be conducted responsibly, with appropriate legal and therapeutic oversight. Limitations explicitly acknowledged include reliance on correlational data, the potential importance of third variables, and the current lack of direct empirical demonstrations linking entheogen‑induced mystical experiences to durable immune changes or clinical remissions. The paper positions the Emxis hypothesis as a testable idea that warrants careful experimental investigation rather than a settled conclusion.